User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy.

Primary tabs

Seremet, Teofila [UCL] Brasseur, Francis [UCL] Coulie, Pierre G. [UCL]

T cell-based cancer immunotherapy relies on advancements made over the last 20 years on the molecular mechanisms underlying the antigenicity of tumors. This review focuses on human tumor antigens recognized by T lymphocytes, particularly the reasons why some are tumor-specific but others are not, and on the immunologic adjuvants used in clinical trials on therapeutic vaccination with defined tumor antigens.

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès restreint
Publication date 2011
Language Anglais
Journal information "The Cancer Journal" - Vol. 17, no.5, p. 325-30 (2011)
Peer reviewed yes
Publisher Lippincott Williams & Wilkins ((United States) Philadelphia)
issn 1528-9117
e-issn 1540-336X
Publication status Publié
Affiliation UCL - SSS/DDUV - Institut de Duve
MESH Subject Adjuvants, Immunologic ; Antigens, Neoplasm ; Antigens, Viral ; Cancer Vaccines ; Humans ; Neoplasms ; T-Lymphocytes
Links
Bibliographic reference Seremet, Teofila ; Brasseur, Francis ; Coulie, Pierre G.. Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy.. In: The Cancer Journal, Vol. 17, no.5, p. 325-30 (2011)
Permanent URL http://hdl.handle.net/2078.1/124124